4D Molecular Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview

4D Molecular Therapeutics

04/11/2022 11:03

* 4D Molecular Therapeutics Inc  FDMT.OQ   FDMT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
November 8 (estimated). 
    * The Emeryville California-based  company is expected to
report 
a 35.9% decrease in revenue to $876.25 thousand from $1.37
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for 4D Molecular
Therapeutics
Inc is for a loss of 91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $15​, above​ its last closing price
of $8.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.87       -0.85      -0.87     Missed  -2.4
 Mar. 31 2022  -0.78       -0.81      -0.82     Missed  -1.2
 Dec. 31 2021  -0.85       -0.86      -0.85     Beat    1.2​
 Sep. 30 2021  -0.83       -0.80      -0.82     Missed  -1.9
 ​​Jun.        -0.68       -0.68      -0.28     Beat    58.8
 30 2021                                                
 Mar. 31 2021  -1.10       -1.10      -0.61     Beat    44.5​
 Dec. 31 2020  -0.66       -0.66      -2.36     Missed  -257.6
 This summary was machine generated November 4 at 11:03 GMT.  All
figures in US dollars  unless otherwise stated